Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has selected Cancer Genetics (CGI) to provide clinical trial services and molecular profiling in treating chronic lymphocytic leukemia(CLL) for international trial locations.
Subscribe to our email newsletter
CGI will leverage its SelectOne program that includes proprietary genomic assays in CLL, data and logistics management, and comprehensive CLIA- and CAP-accredited clinical laboratory testing.
Using CGI’s comprehensive oncology focused menu and proprietary microarrays, SelectOne proposal empowers Gilead to achieve their goals in oncology clinical trials.
The studies consist of testing across flow cytometry, FISH, and molecular diagnostics assays which includes mutational analyses of IGHV, TP53, NOTCH1, and CGI’s proprietary array-CGH assay for mature B-cell neoplasm, MatBA-CLL/SLL.
CGI offers Comprehensive CLL testing, oncologists and community hospitals under its CLL Complete.
CLL Complete includes the assessment of ZAP-70, CD38, and mutational status of IGHV, TP53 and SF3B1, genomic alterations by FISH and by a proprietary genomic microarray – MatBA-CLL /SLL. It also includes a comprehensive report stratifying the risk and potential outcome, to guide disease and patient management.
CGI anticipates the trials to continue for the upcoming years.